Tag Archive for: biotechnology

CellCentric to present inobrodib Phase I multiple myeloma efficacy and safety data at the American Society of Haematology

Inobrodib is a pioneering drug targeting twin tumour drivers p300/CBP, providing a new way to treat specific cancers Objective responses have been observed in multiple settings, including as monotherapy in relapsed refractory multiple myeloma ASH is the annual flagship scientific and clinical haematology meeting which is taking place in New Orleans on 9-13 December 2022 […]

Enzyre closes Series A financing round of EUR 12M to advance pioneering diagnostic technology platform for hemophilia patients

Funds will be used to accelerate development of proprietary ambulant diagnostic platform and establish manufacturing capabilities Plans to expand platform beyond hemophilia A 02 November 2022, Nijmegen, Netherlands: Enzyre, which is developing breakthrough ambulant diagnostic technology for blood coagulation testing, today announced that it has successfully raised EUR 12 million in a Series A financing […]

Gadeta Appoints Scientific Advisory Board and Provides Business Update

Utrecht, Netherlands and Boston, Mass., 20 October 2022: Gadeta B.V. (‘Gadeta’), an innovative clinical-stage biopharmaceutical company pioneering the development of gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for solid tumors, today announced the formation of a Scientific Advisory Board comprised of internationally renowned leaders in oncology, T cell biology and strategic drug development. The Scientific […]

AMSilk Relocate Offices to Support Expansion Plans

The purpose-built offices will support its production of game-changing material solutions on an industrial scale Expanding biotech laboratory, pilot plants and office space, AMSilk embarks on the next stage of its journey to provide biofabricated silk materials across the world Munich, Germany, 10 October 2022 – AMSilk GmbH (“AMSilk”), a world leader in supplying innovative high-performance […]

ImaginAb and Roche have entered a clinical trial supply agreement for provision of atezolizumab (Tecentriq®)1 to Non-Small Cell Lung Cancer Patients Enrolled in ImaginAb’s iPREDICT Phase IIb Study

Los Angeles, California, USA, June 8th, 2022 – ImaginAb Inc., a market leading global biotechnology company focused on developing next generation ImmunoPET imaging agents and therapeutic radiopharmaceuticals (RPT), is pleased to announce that Roche has agreed to provide US approved atezolizumab (Tecentriq®)1, to Non-Small Cell Lung Cancer (NSCLC) patients who are enrolled in ImaginAb’s new Phase IIb […]